Evidence map›Paper›PMID 20813881›Full record

ArticleGenetics2010

When Cre-mediated recombination in mice does not result in protein loss.

Kirsten A Turlo, Sean D Gallaher, Roshni Vora, Frank A Laski, M Luisa Iruela-Arispe

Open access · bronzeAbstract read
In one paragraph

Article in Genetics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Optogenetic Control of Airway Cholinergic NeuronsAmerican journal of respiratory cell and molecular biology · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. De novo generation of adipocytes from circulating progenitor cells in mouse and human adipose tissue.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. VEGF and podocytes in diabetic nephropathy.Seminars in nephrology · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Kirsten A TurloMolecular Biology Institute, University of California, Los Angeles, California 90095, USA.
Sean D Gallaher
Roshni Vora
Frank A Laski
M Luisa Iruela-Arispe
Institute of Molecular Biology · BGInstitut thématique Génétique, génomique et bioinformatique · FRUniversity of California, Los Angeles · US

Funding

VEGF Signaling and Tumor MicroenvironmentR01CA126935 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI IRUELA-ARISPE, M. LUISA · 2007 to 2011
$1.4M
NCI NIH HHS R01 CA126935NCI NIH HHS R01CA126935
6 · The paper itself

Abstract

Cre/loxP recombination enables cellular specificity and, in the case of inducible systems, temporal control of genomic deletions. Here we used a SM22α tamoxifen-inducible Cre line to inactivate β1 integrin in adult smooth muscle. Interestingly, analysis of two distinct β1 loxP transgenic mice revealed vastly different outcomes after β1 integrin deletion. Lethality occurred 4 weeks postinduction in one Cre/loxP line, while no apparent phenotype was seen in the other line. Genetic analysis revealed appropriate DNA excision in both cases; however, differences were found in the degree of protein loss with absolutely no change in protein levels in the model that lacked a phenotype. Seeking to understand protein persistence despite appropriate recombination, we first validated the flox allele using a constitutive Cre line and demonstrated its ability to mediate effective protein inactivation. We then examined the possibility of heterozygous cell selection, protein turnover, and deletion efficiency with no success for explaining the phenotype. Finally, we documented the presence of the Cre-recombination episomal product, which persisted in tissue samples with no protein loss. The product was only noted in cells with low proliferative capacity. These findings highlight the potential for protein expression from the products of Cre-recombinase excised genes, particularly when deletion occurs in low turnover populations.

Indexed as

Recombination, GeneticAllelesAnimalsEmbryo, MammalianFibroblastsGene DeletionHeterozygoteHomozygoteIntegrasesIntegrin beta1KineticsMiceMuscle, Smooth, VascularMyocytes, Smooth MusclePlasmidsCre recombinaseIntegrasesIntegrin beta1

Identifiers

PMID20813881
PMCPMC2975293
OpenAlexW2147927776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.